Seelos Therapeutics (SEEL)
(Delayed Data from NSDQ)
$0.28 USD
-0.01 (-3.68%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $0.30 +0.02 (7.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMSeelos Therapeutics (SEEL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.02 | $30.03 | $4.00 | 5,768.97% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Seelos Therapeutics comes to $17.02. The forecasts range from a low of $4.00 to a high of $30.03. The average price target represents an increase of 5% from the last closing price of $0.29.
Analyst Price Targets (2 )
Broker Rating
Seelos Therapeutics currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
1/7/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
9/21/2023 | The Benchmark Company | Bruce D Jackson | Strong Buy | Strong Buy |
9/21/2023 | Guggenheim Securities | Yatin Suneja | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 3 |
Average Target Price | $17.02 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | NA |